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In the CONCEPTstudy (Reginster J-Y, Dudler J, Blicharski T,
et al. Ann Rheum Dis 2017;76:1537–1543) 800 mg/day of
pharmaceutical-grade Chondroitin Sulfate (CS) was shown
to be superior to placebo and similar to celecoxib in reducing
pain and improving function over 6 months in patients with
symptomatic knee osteoarthritis (OA). We investigate, in the
present study, whether a responder profile to CS could be
defined, i.e. to determine a patient’s profile with the best re-
sponse to the treatment. Subjects from the CS group of the
CONCEPT study were included in the present analysis.
Within the CS group, various groups were created based on
different categories of age, sex, BMI, Kellgren & Laurence
severity, age since OA and baseline level of pain/function. The
non-parametric Kruskal-Wallis (KW) test was applied to com-
pare the VAS Pain/Lequesne Index evolutions between groups
and the Dwass, Steel, Crichlow-Flinger (DSCF) procedure
was used to compute multiple comparisons. The impact of
various covariates on the VAS Pain/Lequesne Index evolution
was assessed by means of a multiple regression. The proba-
bility to respond to CS treatment was significantly associated
with the duration between the date of diagnostic and the initi-
ation of the treatment: higher the duration, lower the response
both for pain and function, particularly for patients with dura-
tion >10 years as compared to patients with duration <5 years.
A significant effect of the baseline function on the improve-
ment of the Lequesne Index is also observed, with a highest
response in patients with the lowest function at baseline. No
other criteria have been found to be associated with the re-
sponse to CS treatment in the CONCEPT study.
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Objectives: Chondroitin sulfate is a symptomatic slow-
acting molecule recommended by ESCEO for the
treatment of osteoarthritis. It is commercialized as pharma-
ceutical grade product and as food supplement in combination
with other components (e.g. methylsulfonylmethane, plant ex-
tracts, vitamins, collagen etc.). Food supplements do not
need to undergo the strict regulatory controls of
pharma grade products, thus composition and the even-
tual presence of contaminants may not be evidenced
before commercialization. Concerns should rise on
the biological efficacy of these formulations. In this
research a systematic multi-analytical approach was
designed to analyze over 25 different food supple-
ments from 8 diverse European countries, in compari-
son to pharmaceutical grade samples.
Methods: Strong anion exchange chromatography, high per-
formance capillary electrophoresis, size exclusion chromatog-
raphy coupled to laser scattering detector and finally
heterocorrelated NMR technique were used to evaluate: a)
content and purity of CS b) presence of Keratan Sulfate
(KS) as contaminant c) CS extractive source.
In vitro model based on human chondrocytes and
synoviocytes were set up for bioactivity comparison, using
time lapse video microscopy, and biomarkers quantifications
via western blotting and ELISA assays.
Results: The analytical approach helped in assessing that
the CS content in food supplements was lower than ex-
pected/declared. In addition KS accounted for up to 30%
contamination of CS in food supplements. After the struc-
tural analysis, the biological efficacy of 5 food supple-
ments was tested in comparison to pharmaceutical prod-
ucts. The results of an in vitro model on synoviocytes and
chondrocytes cells, proved higher cell viability, prolifera-
tion and inflammation reduction (NF-kb mediated
pathway) by the pharmaceutical products while the food
supplements tested were not as effective. A couple of
those appeared also cytotoxic.
Conclusions: Assessment of quality and purity of CS, be-
side the dosage is of key importance to find a robust
correlation between treatment and clinical outcomes in
OA patients.
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